In a significant medical achievement, Apollo Hospitals in Chennai has successfully performed India’s first implantation of the Edwards SAPIEN 3 Ultra RESILIA transcatheter aortic valve (TAVI) on a 70-year-old patient. The patient, who suffered from severe aortic stenosis and had a prior coronary stent, was deemed too high-risk for open-heart surgery. The procedure was led by Dr. G. Sengottuvelu, a senior interventional cardiologist and head of structural interventions.
The innovative RESILIA valve is designed to provide longer durability, resist calcification, and minimize the need for repeat surgeries. This cutting-edge technology offers a safer and more minimally invasive treatment option for patients with severe heart valve disease. According to Ms. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals Group, this breakthrough allows Indian patients to access advanced global technology with proven durability and improved long-term outcomes.
The RESILIA valve has been shown to reduce key risks associated with traditional valve replacement, including structural valve deterioration and paravalvular leak. Dr. Sengottuvelu noted that this marks a new chapter in cardiac care in India, providing patients with a more durable and effective treatment option. Clinical studies have demonstrated that the valve has over 99% freedom from deterioration at eight years, making it one of the most durable options available worldwide.
This milestone procedure highlights the commitment of Apollo Hospitals to providing innovative and cutting-edge medical treatment to patients in India. The introduction of the RESILIA valve is expected to significantly improve the treatment outcomes for patients with severe heart valve disease, offering them a safer and more effective alternative to traditional open-heart surgery. With its proven durability and minimal invasive approach, the RESILIA valve is poised to revolutionize the field of cardiac care in India.